In line with previous reports on the anti-tumor effect of metformin through down-regulating the CyclinD1 level in prostate cancer and breast cancer [52], [53], the reduction of DVL3 expression is also in concomitant with the decreased levels of β-catenin and its downstream target, CyclinD1, which is responsible for cell cycle control. Here, CCND1 is linked to prostate carcinoma.